Emergent Biosolutions Inc Stock Price, News & Analysis

Emergent BioSolutions will participate in key investor conferences in June 2022, including:

• Benchmark Healthcare House Call Virtual 1X1 Conference on June 2.
• NYSE Healthcare & Technology Virtual Investor Access Day on June 8.
• East Coast IDEAS Conference on June 22, featuring a pre-recorded presentation accessible at 6:00 am ET.

Webcast presentations may discuss business developments and financial results, available live and on replay via the Emergent website.

Emergent BioSolutions (EBS) has announced its acquisition of TEMBEXA® from Chimerix for $225 million, enhancing its medical countermeasures portfolio against smallpox. The deal is expected to be accretive and funded by current resources, with deliveries to the U.S. government anticipated in 2022. TEMBEXA, the first FDA-approved antiviral for smallpox, is critical for public health preparedness. The transaction also includes potential milestone payments of up to $100 million and royalties based on future procurement.

Emergent BioSolutions Inc. (NYSE: EBS) announced its 2022 Annual Meeting of Stockholders will be held virtually on May 26, 2022, at 9:00 AM EDT. Stockholders of record can participate via live audio webcast, accessing the meeting through a designated website using their unique Control Number. Those without a Control Number can attend in listen-only mode. Full instructions for participation and ownership verification are available online. A replay of the meeting will also be accessible on the Emergent website.

Emergent BioSolutions (EBS) reported Q1 2022 revenues of $307.5M, down 10% from Q1 2021. Adjusted EBITDA decreased 71% to $36M, while net loss reached $3.7M. Key revenue drivers included $103.6M from anthrax vaccines (up 88%) and $93.1M from nasal naloxone products (up 25%). However, contract development manufacturing (CDMO) revenues fell 67% to $60.8M. The company has suspended CDMO guidance due to uncertainties regarding COVID-19 vaccine requirements. EBS reiterated its 2022 revenue guidance for anthrax vaccines and other products.

Emergent BioSolutions Inc. (NYSE: EBS) announced a conference call on April 28, 2022, at 5:00 PM ET to discuss its Q1 2022 financial results, recent business developments, and revenue guidance for Q2 2022 and the full year 2022.

Investors can participate via telephone or webcast. The toll-free dial-in number is (855) 766-6521, with a conference ID of 3691528. A replay will be available on the company’s website following the call.

Emergent BioSolutions (NYSE: EBS) announced significant governance changes on March 23, 2022. Effective April 1, 2022, Zsolt Harsanyi, Ph.D., will serve as the new chairman of the board, following the elimination of the executive chairman role. Keith Katkin has been appointed as an independent director. Additionally, new chairs for the audit, strategic operations, and scientific review committees have been designated. These changes reflect the company's commitment to improved corporate governance and strategic execution, promoting shareholder value and enhancing operational efficacy.

Emergent BioSolutions (NYSE: EBS) has announced its participation in several upcoming investor conferences. Notable events include the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022, with a fireside chat at 1:30 PM ET, and the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 12:00 PM ET. Additionally, Emergent will attend the Goldman Sachs 7th Annual Leveraged Finance and Credit Conference from May 11 to 13, 2022, with further details to be provided on their website. Webcasts will be available for live viewing and replay.

Emergent BioSolutions (NYSE: EBS) has initiated a Phase 1 study administering stabilized isoamyl nitrite (SIAN) for acute cyanide poisoning treatment. The first participant was dosed on March 11, 2022. This study, funded by BARDA, aims to evaluate SIAN's safety, tolerability, and pharmacokinetics. Targeting 70 healthy participants aged 18-45, SIAN will be developed as an intranasal spray for first responders and civilians. The R&D aligns with Emergent's focus on critical public health threats.

Emergent BioSolutions (EBS) reported Q4 2021 revenues of $723.2 million, a 24% increase from Q4 2020. For FY 2021, total revenues reached $1.79 billion, up 15% year-over-year, while Adjusted EBITDA was $517.6 million (down 18%). The company revised its 2022 guidance downwards, expecting revenues of $1.3 to $1.4 billion due to operational adjustments. Key highlights included a 56% revenue increase in nasal naloxone products and a new supply agreement with Sandoz for an authorized generic of NARCAN. However, net income declined 24% for the year.